Leucine Rich Bio, South Asia’s pioneering microbiome company, has achieved a significant milestone by earning NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation, further cementing its leadership in microbiome diagnostics. This follows its earlier accreditation from NABH (National Accreditation Board for Hospitals & Healthcare Providers), making it the only microbiome-focused company in India to hold both prestigious recognitions, alongside ISO 9001:2015 (Quality Management Systems) and ISO 17025 (Testing & Calibration Laboratories) certifications.
These accreditations position Leucine Rich Bio as a standout in the Indian healthcare and diagnostics landscape:
NABL accreditation attests to the company’s technical competence, consistency, and compliance with ISO/IEC 17025 standards, reinforcing the reliability of its testing protocols.
NABH accreditation highlights excellence in clinical quality, operational transparency, and patient safety.
ISO 9001:2015 underlines a commitment to global standards in quality management.
ISO 17025 guarantees the accuracy and validity of the company’s laboratory processes.
Collectively, these certifications reflect Leucine Rich Bio’s rigorous approach to quality at every stage — from sample collection to AI-powered analysis and reporting. This ensures high diagnostic precision, clinical confidence, and safer patient outcomes in the evolving field of microbiome-based healthcare.
“These accreditations mark a crucial step forward in legitimizing microbiome science as both clinically relevant and scientifically robust,” said Prabhath Manjappa, Co-founder & Chief Product Officer. “They reinforce our mission to transform preventive healthcare through actionable, data-driven insights.”
Echoing this sentiment, Dr. Debojyoti Dhar, Co-founder and Director, stated, “This recognition from NABL and NABH is a defining moment for us as we continue to build a trusted and dependable ecosystem for microbiome testing solutions.”
Kumar Sankaran, CEO of Leucine Rich Bio, added, “This is not just a company achievement — it’s a milestone for microbiome-led medicine in India. By integrating both international and national standards, we’re setting a new bar for quality, safety, and diagnostic excellence in this field.”
As the microbiome sector gains momentum globally, Leucine Rich Bio continues to lead the way by combining cutting-edge science with world-class operational standards — ensuring the benefits of personalized, preventive healthcare reach a broader population with confidence and credibility.